Vijay S. Choksi and Shane A. Pennington —
Much of the discussion surrounding federal cannabis rescheduling has focused on what the industry stands to gain from Schedule III treatment. For operators, investors, and regulators, however, the more significant development may be something else entirely: the line federal regulators have drawn within the cannabis industry itself.
In April, the Department of Justice and Drug Enforcement Administration (“DEA”) placed Food and Drug Administration-approved marijuana products and marijuana products subject to qualifying state medical marijuana licenses in Schedule III. Marijuana outside those categories, including marijuana sold through state adult-use programs, remains in Schedule I while the broader rescheduling process continues. The same federal action also created an expedited DEA registration pathway for qualifying state medical marijuana licensees. The result is more than a scheduling change. It creates a new federal distinction between medical and adult-use cannabis at a time when many state regulatory systems have spent years moving in the opposite direction. Across the country, states have increasingly integrated medical and adult-use operations, allowing businesses to share facilities, personnel, management, and infrastructure. Federal law is now introducing a separation that many state markets were never designed to accommodate. That emerging tension between state integration and federal separation may ultimately have a greater impact on the industry than rescheduling itself.